...
首页> 外文期刊>Stem cells translational medicine. >Characterization of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis
【24h】

Characterization of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis

机译:自体间充质干细胞来源的神经祖细胞的表征作为干细胞在多发性硬化症中枢神经系统应用的可行来源

获取原文
           

摘要

Bone marrow mesenchymal stem cell-derived neural progenitors (MSC-NPs) are a potential therapeutic source of cells that have been shown to be efficacious in a preclinical model of multiple sclerosis (MS). To examine the feasibility of using MSC-NPs as an autologous source of cells to promote central nervous system (CNS) repair in MS, this study characterized human MSC-NPs from a panel of both MS and non-MS donors. Expanded MSCs showed similar characteristics in terms of growth and cell surface phenotype, regardless of the donor disease status. MSC-NPs derived from all MSCs showed a consistent pattern of gene expression changes that correlated with neural commitment and increased homogeneity. Furthermore, the reduced expression of mesodermal markers and reduced capacity for adipogenic or osteogenic differentiation in MSC-NPs compared with MSCs suggested that MSC-NPs have reduced potential of unwanted mesodermal differentiation upon CNS transplantation. The immunoregulatory function of MSC-NPs was similar to that of MSCs in their ability to suppress T-cell proliferation and to promote expansion of FoxP3-positive T regulatory cells in vitro. In addition, MSC-NPs promoted oligodendroglial differentiation from brain-derived neural stem cells that correlated with the secretion of bioactive factors. Our results provide a set of identity characteristics for autologous MSC-NPs and suggest that the in vitro immunoregulatory and trophic properties of these cells may have therapeutic value in the treatment of MS.
机译:骨髓间充质干细胞源性神经祖细胞(MSC-NPs)是潜在的治疗性细胞来源,已在多发性硬化症(MS)的临床前模型中显示出这种作用是有效的。为了检验使用MSC-NP作为细胞自体来源促进MS中枢神经系统(CNS)修复的可行性,本研究从一组MS和非MS供体中鉴定了人类MSC-NP。无论供体疾病状况如何,扩增的MSC在生长和细胞表面表型方面均显示出相似的特征。源自所有MSC的MSC-NPs表现出与神经承诺和同质性增加相关的一致的基因表达变化模式。此外,与MSC相比,MSC-NP中中胚层标记物的表达降低以及成脂或成骨分化能力降低,这表明MSC-NP在中枢神经系统移植后具有不希望的中胚层分化潜力。 MSC-NP的免疫调节功能在体外具有抑制T细胞增殖和促进FoxP3阳性T调节细胞扩增的能力,与MSC相似。此外,MSC-NPs促进了脑源性神经干细胞的少突胶质细胞分化,这与生物活性因子的分泌有关。我们的结果为自体MSC-NP提供了一组身份特征,并表明这些细胞的体外免疫调节和营养特性可能在MS的治疗中具有治疗价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号